TILT Biotherapeutics Initiates Collaboration With Merck KGaA, Darmstadt, Germany and Pfizer Investigating the Combination of Oncolytic Virus, TILT-123, And Anti-PDL1 Antibody, Avelumab. Read the press release in English here.
Read the news in Finnish from Bonnier Business Forum´s website or from the link below
TILT Biotherapeutics solmi yhteistyösopimuksen Merckin ja Pfizerin kanssa